For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 5,759,473 | |||
| General and administrative | 9,343,497 | |||
| Total expenses | 15,102,970 | |||
| Loss from operations | -15,102,970 | |||
| Foreign exchange losses | -56,555 | |||
| Investment income | 948,122 | |||
| Loss on issuance of convertible preferred stock and warrants | 321,499,041 | |||
| Warrant issuance cost | 3,102,649 | |||
| Changes in fair value of the warrant liability | -45,389,916 | |||
| Net (loss) income | -293,423,177 | |||
| Basic EPS | -34.67 | |||
| Diluted EPS | -34.67 | |||
| Basic Average Shares | 8,463,581 | |||
| Diluted Average Shares | 8,463,581 | |||
Minerva Neurosciences, Inc. (NERV)
Minerva Neurosciences, Inc. (NERV)